RAP-219
Treatment-Resistant Epilepsy / Focal Onset Seizures
Key Facts
About Rapport Therapeutics
Rapport Therapeutics is a clinical-stage biotech company founded in 2022 with a mission to develop precision medicines for complex neurological disorders by targeting receptor-associated proteins (RAPs). The company achieved a successful IPO in May 2024, raising significant capital to advance its lead clinical program, RAP-219, for treatment-resistant epilepsy and other indications. Its core strategy leverages a proprietary RAP platform to create neuroanatomically specific therapies, aiming to overcome the pervasive side effects that have plagued central nervous system drug development.
View full company profileAbout Rapport Therapeutics
Rapport Therapeutics is a clinical-stage biotech company founded in 2022 with a mission to develop precision medicines for complex neurological disorders by targeting receptor-associated proteins (RAPs). The company achieved a successful IPO in May 2024, raising significant capital to advance its lead clinical program, RAP-219, for treatment-resistant epilepsy and other indications. Its core strategy leverages a proprietary RAP platform to create neuroanatomically specific therapies, aiming to overcome the pervasive side effects that have plagued central nervous system drug development.
View full company profileAbout Rapport Therapeutics
Rapport Therapeutics is a clinical-stage biotech company founded in 2022 with a mission to develop precision medicines for complex neurological disorders by targeting receptor-associated proteins (RAPs). The company achieved a successful IPO in May 2024, raising significant capital to advance its lead clinical program, RAP-219, for treatment-resistant epilepsy and other indications. Its core strategy leverages a proprietary RAP platform to create neuroanatomically specific therapies, aiming to overcome the pervasive side effects that have plagued central nervous system drug development.
View full company profile